Teva Pharmaceutical Industries Ltd. has created a global specialty medicines group.

Teva Pharmaceutical Industries, global specialty medicines group, Rob Koremans, Jeremy Levin, specialty pharmaceuticals, specialty drug, specialty medicines, Dipankar Bhattacharjee, Larry Downey, Teva US Brands, generic drug

Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks

Teva forms global specialty drug group

April 24th, 2013

JERUSALEM – Teva Pharmaceutical Industries Ltd. has created a global specialty medicines group.

The Israel-based drug maker said Wednesday said the newly formed group will leverage the company's well-established generic drug presence for its specialty pharmaceuticals offering.

Teva said Rob Koremans will serve as president and chief executive officer of the new Global Specialty Medicines (GSM) unit. He also will continue to serve on Teva's executive committee and report to Jeremy Levin, president and CEO of Teva Pharmaceutical Industries.

"The newly created Global Specialty Medicines group significantly reinforces Teva's commitment to our patients, customers and health care providers, as it combines the strong local presence we have established in high-quality and accessible generics with our global scale and capabilities in specialty medicines," Levin stated. "The GSM group will work seamlessly with our regional generics teams. They will complement each other and establish a single, differentiated Teva presence in the market.

He added, "The creation of this group is a stepping stone in our strategy to optimize our commercialization, and it paves the path forward to make Teva the most indispensable medicines company for the world."

Teva also announced that Dipankar Bhattacharjee, formerly senior vice president for Western Europe, has been promoted to president and CEO of Generics Europe, reporting to Levin. Bhattacharjee also joins the Teva executive team.

In addition, Larry Downey, formerly executive vice president of Teva US Brands, has been appointed president of North America Specialty Medicines, reporting to Koremans.

Teva has an "impressive portfolio" in the specialty drug arena, according to Koremans. "This move will further emphasize and strengthen our leadership and innovation in this field," he commented. "Teva's unique capabilities in specialty pharmaceuticals are now concentrated in the new GSM group, so we can deliver more effectively on our commitment to our patients and other stakeholders."

More Supplier News Breaks >>